Latest Administration News

Telix Pharmaceuticals has secured FDA agreement on a resubmission plan for its glioma imaging agent TLX101-CDx, aiming for a Q4 2025 filing that includes additional efficacy data. The FDA signals likely expedited review, underscoring the unmet medical need.

Alterity Therapeutics has raised A$20 million through a strategic placement to advance its promising ATH434 treatment for Multiple System Atrophy, backed by encouraging Phase 2 trial results. The capital injection strengthens the company’s balance sheet as it prepares for regulatory discussions with the FDA.

EMU NL has announced a non-renounceable entitlement offer to raise approximately $1.83 million to fund exploration at its Georgetown and Badja projects, while facing significant governance challenges ahead of a pivotal shareholder meeting.

Imagion Biosystems has reached key milestones in its MagSense® HER2 breast cancer imaging program, including starting manufacturing for its Phase 2 trial and launching an AI imaging protocol collaboration with Wayne State University.

Wesfarmers Limited has updated its dividend details, confirming a fully franked ordinary dividend of AUD 1.11 per share payable on 7 October 2025, with shareholders able to receive payments in AUD, NZD, or GBP.

PRL Global Limited has cleared all hurdles to acquire Centrex Ltd and Agriflex Pty Ltd, including the Ardmore Phosphate Mine, with operations already resuming and first shipments expected later this year.

Australian United Investment Company Limited has updated its dividend announcement to include the Dividend Reinvestment Plan issue price, confirming a fully franked total dividend of AUD 0.28 per share for the period ending June 2025.

Compumedics has secured FDA clearance for its single-use Somfit®D device, effectively doubling its addressable U.S. home sleep testing market to an estimated US$240 million annually. This milestone positions the company to capture significant market share with a dual-platform EEG-based solution.

Haranga Resources has successfully commissioned the water treatment plant at its Lincoln Gold Project and begun dewatering, paving the way for its maiden underground drilling program and a JORC resource update by year-end.

Amplia Therapeutics has commenced dosing the first patient in its new pancreatic cancer trial combining narmafotinib with FOLFIRINOX chemotherapy, marking a key milestone in its drug development journey.

Great Northern Minerals Limited has addressed an ASX query regarding the delayed filing of director interest notices, attributing the lapse to an administrative oversight related to option expiry. The company reassures investors that compliance frameworks remain robust.

Lincoln Minerals Limited has announced a supplementary prospectus to raise an additional $750,000 through a Follow-on Placement, responding to strong investor demand beyond its initial entitlement offer.